Rosa's Toufigh Gordi to Present at 2nd Annual Pediatric Pharmacology Conference 2012
Integration of PK/PD and mechanistic physiological models improves drug development in infants.

SAN CARLOS, CA, January 23, 2012 /24-7PressRelease/ -- Rosa & Co. LLC, a drug development advisory firm with expertise in drug-disease modeling and simulation, today announced that its Dr. Toufigh Gordi, President of PKPD and Clinical Pharmacology Services, will present the results of an AMS microdosing study in infants at the 2nd Annual Pediatric Pharmacology Conference in Philadelphia, PA on January 26, 2012. Dr. Gordi will give a 30-minute scientific presentation entitled "Pediatric PK Modeling using AMS Data and PhysioPD Modeling of Ursodiol in a Neonate Clinical Trial". The talk will describe the use of microdosing and AMS data for development of both PK/PD and mechanistic physiological models, and how the resulting new insights can improve drug development practice in pediatric and other sensitive populations. The presentation will also highlight how incorporation of PK/PD data into a physiological model can provide deeper insight into mechanisms of patient variability.

"We are pleased to present the next step of our research into how microdosing, AMS data, and modeling can be combined to improve drug development for pediatrics. PhysioPD modeling allows greater insight into the data, revealing novel insights about patient variability, mechanisms of action, and the implications for pediatric clinical studies." said Dr. Rebecca Baillie, Rosa's Chief Scientist.

Press Release Contact Information:

Rebecca Baillie
Rosa & Co
Chief Scientist
751 Laurel St., Ste. 127
San Carlos, CA
USA 94070
Voice: 4083709800
Website: Visit Our Website